XTX Topco’s Iterum Therapeutics ITRM Stock Holding History

XTX Topco’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-49,380	Closed	-$1.48K	–	4418
2026 Q1	$1.48K	Buy	+49,380	New	+$12.4K	﹤0.01%	3769
2024 Q4	–	Sell	-33,040	Closed	-$36K	–	2597
2024 Q3	$36K	Buy	+33,040	New	+$39.3K	﹤0.01%	1750
2022 Q1	–	Sell	-2,577	Closed	-$15K	–	808
2021 Q4	$15K	Buy	2,577 +103	+4%	+$796	0.01%	637
2021 Q3	$21K	Buy	+2,474	New	+$30.5K	0.01%	638
2021 Q2	–	Sell	-860	Closed	-$18K	–	948
2021 Q1	$18K	Buy	+860	New	+$20.5K	0.01%	658

Other funds holding ITRM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

CCMW

Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

XTX Topco's ITRM Position: Q2 2026 in Review

XTX Topco sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 49,380 shares — an estimated $1.48K sold.

XTX Topco first reported a position in ITRM in Q1 2021 and held it in 5 quarters. The position peaked at $36K in Q3 2024. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

XTX Topco reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 49,380 Iterum Therapeutics shares in Q2 2026, an estimated $1.48K.
XTX Topco first reported a position in Iterum Therapeutics in Q1 2021 and held it in 5 quarters.
XTX Topco's Iterum Therapeutics position peaked at $36K in Q3 2024.
2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.